GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » Capital Expenditure

NextCell Pharma AB (OSTO:NXTCL) Capital Expenditure : kr-0.37 Mil (TTM As of May. 2024)


View and export this data going back to 2017. Start your Free Trial

What is NextCell Pharma AB Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

NextCell Pharma AB's cash flow for capital expenditures for the three months ended in May. 2024 was kr0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in May. 2024 was kr-0.37 Mil.

NextCell Pharma AB Capital Expenditure Historical Data

The historical data trend for NextCell Pharma AB's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB Capital Expenditure Chart

NextCell Pharma AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only -0.40 -0.79 -0.73 -7.59 -4.10

NextCell Pharma AB Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.22 -0.29 -0.04 -0.04 -

NextCell Pharma AB Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » Capital Expenditure
Comparable Companies
OSTO:BIOVIC B OSTO:ALZ OSTO:ELIC XSAT:CESSA OSTO:ACE OSTO:LIPUM OSTO:SIMRIS B OSTO:ZICC NGM:GTAB B OSTO:ISOFOL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
65G:Germany
Address
Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
Website
http://www.nextcellpharma.com
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB Headlines

No Headlines